Calcinosis in rheumatic diseases

Anna Rychlewska-Hańczewska; Mariusz Puszczewicz

eISSN: 2084-9834
ISSN: 0034-6233

Reumatologia/Rheumatology

Current issue Archive Manuscripts accepted About the journal Supplements Editorial board Reviewers Abstracting and indexing Subscription Contact Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

2/2007
vol. 45

Send email

Copy url:

abstract:

Calcinosis in rheumatic diseases

Anna Rychlewska-Hańczewska

,

Mariusz Puszczewicz

Reumatologia 2007; 45, 2:97-101

Online publish date: 2007/04/25

View full text Get citation

Clacinosis occurs in damaged or devitalized tissues in the presence of normal calcium/phosphorus metabolism. It is often noted in the subcutaneous tissues in the course of connective tissues diseases – primarily systemic lupus erythematosus systemicus, sclerodermia and dermatomyositis – and may involve a relatively localized area or be widespread. The aim of the study was to discuss the classification, pathogenesis, clinical features and treatment of calcinosis in rheumatic diseases. The calcinotic accumulations may lead secondarily to muscle atrophy, join contractures and skin ulceration complicated by recurrent episodes of local inflammation and infection. Warfarin, colchicines, probenecid, bisphosphonates, diltiazem, minocycline, aluminium hydroxide, salicylate, surgical extirpation and carbon dioxide laser therapies have been used in the treatment of calcinosis. However, that kind of medication has not convincingly prevented or reduced calcinosis.

keywords:

calcinosis, lupus erythematosus systemicus, sclerodermia, dermatomyositis

EVENTS/KONFERENCJE

BOOKS/KSIĄŻKI

Calcinosis in rheumatic diseases

Anna Rychlewska-Hańczewska , Mariusz Puszczewicz

calcinosis, lupus erythematosus systemicus, sclerodermia, dermatomyositis

Anna Rychlewska-Hańczewska

,

Mariusz Puszczewicz